Drug Trial Radar · NCT02155205
A Thorough QT Study of Telotristat Etiprate
Last checked: Nov 20, 2026Latest source record: Sep 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 2014
Primary completion
Aug 2014
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.
Conditions
- QT Interval
Interventions
Telotristat etiprateDrug
1500 mg telotristat etiprate (six 250 mg tablets)
PlaceboDrug
Matching placebo
MoxifloxacinDrug
400 mg moxifloxacin (one 400 mg tablet)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline QT interval corrected for heart rateTime frame: Days 1-3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lexicon Investigational Site
Evansville, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.